Literature DB >> 25748687

The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse.

S J Coles1,2, M N Gilmour2, R Reid2, S Knapper2, A K Burnett2, S Man2, A Tonks2, R L Darley2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25748687     DOI： 10.1038/leu.2015.62

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  18 in total

1.  CD200 as a prognostic factor in acute myeloid leukaemia.

Authors:  A Tonks; R Hills; P White; B Rosie; K I Mills; A K Burnett; R L Darley
Journal:  Leukemia       Date:  2007-01-25       Impact factor: 11.528

2.  Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study.

Authors:  Anjali Shah; Therese M-L Andersson; Bernard Rachet; Magnus Björkholm; Paul C Lambert
Journal:  Br J Haematol       Date:  2013-06-21       Impact factor: 6.998

3.  Functional unresponsiveness and replicative senescence of myeloid leukemia antigen-specific CD8+ T cells after allogeneic stem cell transplantation.

Authors:  Gregory L Beatty; Jasmine S Smith; Ran Reshef; Kunal P Patel; Theresa A Colligon; Barbara A Vance; Noelle V Frey; F Brad Johnson; David L Porter; Robert H Vonderheide
Journal:  Clin Cancer Res       Date:  2009-07-14       Impact factor: 12.531

4.  CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia.

Authors:  Carmen Scheibenbogen; Anne Letsch; Eckhard Thiel; Alexander Schmittel; Volker Mailaender; Steffi Baerwolf; Dirk Nagorsen; Ulrich Keilholz
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

5.  Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy.

Authors:  Anke Kretz-Rommel; Fenghua Qin; Naveen Dakappagari; Roxanne Cofiell; Susan J Faas; Katherine S Bowdish
Journal:  J Immunol       Date:  2008-01-15       Impact factor: 5.422

Review 6.  Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.

Authors:  Jing Lu; Linda Lee-Gabel; Michelle C Nadeau; Thomas M Ferencz; Scott A Soefje
Journal:  J Oncol Pharm Pract       Date:  2014-06-09       Impact factor: 1.809

7.  Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

Authors:  Jaikumar Duraiswamy; Karen M Kaluza; Gordon J Freeman; George Coukos
Journal:  Cancer Res       Date:  2013-04-30       Impact factor: 12.701

Review 8.  Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention.

Authors:  Wieger J Norde; Willemijn Hobo; Robbert van der Voort; Harry Dolstra
Journal:  Blood       Date:  2012-05-04       Impact factor: 22.113

9.  CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia.

Authors:  S J Coles; E C Y Wang; S Man; R K Hills; A K Burnett; A Tonks; R L Darley
Journal:  Leukemia       Date:  2011-01-28       Impact factor: 11.528

10.  IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells.

Authors:  Saskia J A M Santegoets; Annelies W Turksma; Megan M Suhoski; Anita G M Stam; Steve M Albelda; Erik Hooijberg; Rik J Scheper; Alfons J M van den Eertwegh; Winald R Gerritsen; Daniel J Powell; Carl H June; Tanja D de Gruijl
Journal:  J Transl Med       Date:  2013-02-12       Impact factor: 5.531
View more
  14 in total

1.  Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication.

Authors:  Gang An; Chirag Acharya; Xiaoyan Feng; Kenneth Wen; Mike Zhong; Li Zhang; Nikhil C Munshi; Lugui Qiu; Yu-Tzu Tai; Kenneth C Anderson
Journal:  Blood       Date:  2016-07-14       Impact factor: 22.113

2.  A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia.

Authors:  Shannon K Oda; Andrew W Daman; Nicolas M Garcia; Felecia Wagener; Thomas M Schmitt; Xiaoxia Tan; Aude G Chapuis; Philip D Greenberg
Journal:  Blood       Date:  2017-10-17       Impact factor: 22.113

3.  Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine.

Authors:  Myrna R Nahas; Dina Stroopinsky; Jacalyn Rosenblatt; Leandra Cole; Athalia R Pyzer; Eleni Anastasiadou; Anna Sergeeva; Adam Ephraim; Abigail Washington; Shira Orr; Malgorzata McMasters; Matthew Weinstock; Salvia Jain; Rebecca K Leaf; Haider Ghiasuddin; Maryam Rahimian; Jessica Liegel; Jeffrey J Molldrem; Frank Slack; Donald Kufe; David Avigan
Journal:  Br J Haematol       Date:  2019-03-03       Impact factor: 6.998

4.  MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs.

Authors:  A R Pyzer; D Stroopinsky; J Rosenblatt; E Anastasiadou; H Rajabi; A Washington; A Tagde; J-H Chu; M Coll; A L Jiao; L T Tsai; D E Tenen; L Cole; K Palmer; A Ephraim; R K Leaf; M Nahas; A Apel; M Bar-Natan; S Jain; M McMasters; L Mendez; J Arnason; B A Raby; F Slack; D Kufe; D Avigan
Journal:  Leukemia       Date:  2017-05-30       Impact factor: 11.528

5.  Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.

Authors:  C Krupka; P Kufer; R Kischel; G Zugmaier; F S Lichtenegger; T Köhnke; B Vick; I Jeremias; K H Metzeler; T Altmann; S Schneider; M Fiegl; K Spiekermann; P A Bauerle; W Hiddemann; G Riethmüller; M Subklewe
Journal:  Leukemia       Date:  2015-08-04       Impact factor: 11.528

6.  Phenotypic and Functional Characterization of Monoclonal Antibodies with Specificity for Rhesus Macaque CD200, CD200R and Mincle.

Authors:  Siddappa N Byrareddy; Dawn Little; Ann E Mayne; Francois Villinger; Aftab A Ansari
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

7.  Leukemia-induced dysfunctional TIM-3+CD4+ bone marrow T cells increase risk of relapse in pediatric B-precursor ALL patients.

Authors:  Franziska Blaeschke; Semjon Willier; Dana Stenger; Mareike Lepenies; Martin A Horstmann; Gabriele Escherich; Martin Zimmermann; Francisca Rojas Ringeling; Stefan Canzar; Theresa Kaeuferle; Meino Rohlfs; Vera Binder; Christoph Klein; Tobias Feuchtinger
Journal:  Leukemia       Date:  2020-03-13       Impact factor: 11.528

8.  Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors.

Authors:  Daniela Damiani; Mario Tiribelli; Donatella Raspadori; Santina Sirianni; Alessia Meneghel; Margherita Cavalllin; Angela Michelutti; Eleonora Toffoletti; Antonella Geromin; Erica Simeone; Monica Bocchia; Renato Fanin
Journal:  Oncotarget       Date:  2015-10-06

Review 9.  Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.

Authors:  Christian M Schürch
Journal:  Front Oncol       Date:  2018-05-18       Impact factor: 6.244

10.  CD200 Induces Epithelial-to-Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma via β-Catenin-Mediated Nuclear Translocation.

Authors:  Seung-Phil Shin; A-Ra Goh; Hyeon-Gu Kang; Seok-Jun Kim; Jong-Kwang Kim; Kyung-Tae Kim; John H Lee; Yong-Soo Bae; Yuh-Seog Jung; Sang-Jin Lee
Journal:  Cancers (Basel)       Date:  2019-10-17       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.